Broder; Cancer Act’s Special Authorities Don’t Give Director Immunity For NIH, HHS
In Brief: House, Senate Enact FY ’92 Budget Bills For NCI That Differ By $200 Million; Senate’s Is Higher
Bypass Budget Is Realistic, Defensible Plan, Broder Says
Broder On FDA: Don’t Blame Them For Doing Their Jobs (They Have To Work At Parklawn)
Tipping Resigned Forom ACS Following Volunteer Discontent
NSABP Sees Groups To Join Breast Cancer Prevention Trial
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ









